Walleye Capital
DFTX

Walleye Capital’s Definium Therapeutics DFTX Stock Holding History

Walleye Capital’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$936K Buy
+19,900
New +$492K ﹤0.01% 2184
2025
Q4 		– Sell
-24,900
Closed -$294K – 4924
2025
Q3 		$294K Buy
24,900
+3,700
+17% +$34.5K ﹤0.01% 3021
2025
Q2 		$138K Buy
21,200
+1,300
+7% +$8.55K ﹤0.01% 3604
2025
Q1 		$116K Buy
+19,900
New +$143K ﹤0.01% 3554
2024
Q4 		– Sell
-9,800
Closed -$55.8K – 5275
2024
Q3 		$55.8K Buy
9,800
+4,100
+72% +$28.5K ﹤0.01% 4610
2024
Q2 		$41.1K Buy
+5,700
New +$49.9K ﹤0.01% 4982

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Walleye Capital's DFTX Position: Q2 2026 in Review

Walleye Capital reduced its Definium Therapeutics (DFTX) stake by 42% in Q2 2026, selling an estimated $367K and leaving 20,643 shares worth $971K. The position accounts for ﹤0.01% of the portfolio, ranked #2150.

Walleye Capital first reported a position in DFTX in Q2 2024 and has held it in 4 quarters since. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Walleye Capital held 20,643 shares of Definium Therapeutics worth $971K as of Q2 2026.
  • Walleye Capital sold 14,842 Definium Therapeutics shares in Q2 2026, an estimated $367K.
  • Definium Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #2150 holding.
  • Walleye Capital first reported a position in Definium Therapeutics in Q2 2024 and has held it in 4 quarters since.
  • 361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.